Dr. Armstrong Discusses ARCHES Trial in Prostate Cancer

Video

Andrew J. Armstrong, MD, associate professor of medicine and surgery, Department of Medicine, Duke University School of Medicine, Duke Cancer Institute, discusses the ARCHES trial in patients with metastatic hormone-sensitive prostate cancer.

Andrew J. Armstrong, MD, associate professor of medicine and surgery, Department of Medicine, Duke University School of Medicine, Duke Cancer Institute, discusses the ARCHES trial in patients with metastatic hormone-sensitive prostate cancer.

The study, which was presented at the 2019 Genitourinary Cancers Symposium, was a global phase III randomized trial in 1150 men with metastatic prostate cancer who had just begun treatment with androgen deprivation therapy (ADT) or who had just completed treatment with docetaxel and ADT. The patients were randomized 1:1 to receive either ADT alone or ADT plus enzalutamide (Xtandi) at 160 mg daily.

The primary endpoint of the trial was radiographic progression-free survival (rPFS), which has been a regulatory accepted endpoint, similar to metastasis-free survival. Because these men had metastatic disease, the goal of the trial was to delay radiographic progression or death. This is a clinically meaningful endpoint, Armstrong says, because you are preventing the need for a change in therapy, pain progression, and overall quality of life deterioration. In other studies, improvements in rPFS have also been associated with long-term improvements in overall survival.

Findings from ARCHES demonstrated a 61% reduction in the risk of radiographic progression or death with the addition of enzalutamide to treatment.

Related Videos
Emmanuel Antonarakis, MD, associate director, Translational Research, Masonic Cancer Center, University of Minnesota, Clark Endowed Professor of Medicine, University of Minnesota Medical School
Gautam Jha, MD, medical director, M Health Fairview Masonic Cancer Clinic and the Advanced Treatment Center at the M Health Fairview Clinics and Surgery Center—Minneapolis, chair, cancer committee, M Health Fairview Ridges Hospital
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute